NCT01436539Unknown4 期
A Multi-center, Open Label, Randomized Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Capsule Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients
Jun Cheng1 个研究点 分布在 1 个国家目标入组 300 人开始时间: 2011年9月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 发起方
- 入组人数
- 300
- 试验地点
- 1
- 主要终点
- Proportions of subjects with histological response in treatment and control group.
研究概览
简要总结
The purpose of the study is to evaluate the effects and safety of Adefovir Dipivoxil plus polyene phosphatidylcholine compared to Adefovir Dipivoxil alone in patients with chronic hepatitis B.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males and females between the age of 18 to 65 years with chronic hepatitis B.
- •HBsAg positive for a minimum of 6 months.
- •HBV DNA ≥4 log10 copies/ml, and ≤ 6 log10 copies/mL
- •Alanine aminotransferase (ALT) ≥ 2 times the upper limit of normal(ULN) and ≤10 times ULN, and documented ALT abnormal within 6 month prior to the study screening.
- •Had a liver biopsy performed within 6 months prior to randomization and has readable biopsy slides or agrees to have a biopsy performed prior to entry.
- •Willing and able to provide written informed consent.
排除标准
- •Received any nucleoside, nucleotide or interferon therapy within 6 months prior to the screening.
- •Previous treatment with lamivudine, adefovir, entecavir or telbivudine and occurred viral breakthrough or genotype resistance.
- •Received immunosuppressive agents or other immunoregulates (including thymosin),systemic cytotoxic drugs, other antiviral agents including Chinese herb medicine within 6 months prior to the screening.
- •Active alcohol intake( more than 20g/d for female or more than 30g/d for male) or drug abuse within 1 year prior to screening. Alcohol or drug abuse considered by the investigator to be sufficient to hinder compliance with treatment, participation in the study or interpretation of results.
- •ALT is greater than 10 times ULN at screening or has the history of transient decompensated liver disease due to acute exacerbation.
- •Any of the laboratory test at screening as the following :
- •serum creatinine > 1.5 mg/dl ;
- •prothrombin time ≥ 4 seconds prolonged or PTA <60%;
- •serum albumin<32 g/L;
- •serum bilirubin>3.0mg/dL;
- •Hemoglobin<11g/dL(males) or <10 g/dL(females), white blood cells count<3.5 x 10^9/L, absolute neutrophil count <1.5 x 10^9/L, platelets<80 x 10^9/L.
- •Patient is coinfected with HCV, HDV or HIV.
- •Hepatocellular carcinoma (HCC), or the presence of a mass on imaging studies of the liver that is suggest of HCC, or an alpha-fetoprotein (AFP)> 500ng/mL.
- •Decompensated liver disease as defined by serum bilirubin >3mg/dL, prothrombin time≥ 4 seconds prolonged, a serum albumin<32g/L, or a history of ascites, variceal bleeding or hepatic encephalopathy.
- •Presence of other causes of liver disease (i.e.alcoholic liver disease,autoimmune hepatitis, hemochromatosis, Wilson disease, nonalcoholic steatohepatitis, alpha-1anti-trypsin deficiency).
- •Any serious or active medical or psychiatric illnesses other than hepatitis B which, in the opinion of the investigator, would interfere with patient treatment, assessment or compliance with the protocol. This would include, may not limit to, renal, cardiac, pulmonary, vascular, neurogenic, digestive, metabolic (diabetes, thyroid disorders, adrenal disease), immunodeficiency disorders, active infection or cancer.
- •Patient is pregnant or breast-feeding.
- •Planned for liver transplantation or previous liver transplantation.
- •Need take hepatotoxic drugs (e.g.,dapsone, erythromycin, fluconazole, rifampin, etc) and nephrotoxic drugs (e.g., NSAIDs, aminoglycosides, amphotericin B, foscarnet, etc.) for long time.
- •History of hypersensitivity to nucleoside analogues.
- •Previous (or planned) participation in an investigational trial involving administration of investigational compound within 12 weeks prior to the study screening.
- •Poor compliance of the patient considered by investigator.
研究组 & 干预措施
Adefovir Dipivoxil and polyene phosphatidylcholine
Experimental
Adefovir Dipivoxil 10 mg once daily for 48 weeks plus Polyene phosphatidylcholine (PPC) 456 mg three times per day for 48 weeks
干预措施: Adefovir Dipivoxil and polyene phosphatidylcholine (Drug)
Adefovire Dipivoxil
Active Comparator
Adefovir Dipivoxil 10 mg once daily for 48 weeks
干预措施: Adefovir Dipivoxil (Drug)
结局指标
主要结局
Proportions of subjects with histological response in treatment and control group.
时间窗: at week 48
次要结局
- Liver stiffness values reduction from baseline by Fibroscan(at week 48)
- ALT normalization rate and range(at week 12 and 48)
- Proportions of subjects in each group who achieve: HBV DNA < 300 copies/mL(at week 48)
- Mean log10 reduction from baseline in HBVDNA(at week 12, 24, 48)
- HBeAg loss and HBe seroconversion(at week 12 and 48)
- HBsAg loss and HBs seroconversion(at week 12 and 48)
- Improvement in symptoms score(at week 12, 24 and 48)
- Frequency of adverse events(up to 60 weeks)
- Frequency of serious adverse events(up to 60 weeks)
- Frequency of discontinuations from study drug due to adverse events or laboratory abnormalities.(up to 60 weeks)
研究者
Jun Cheng
Vice president
Capital Medical University
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Efficacy and Safety Study of Adefovir Dipivoxil to Treat Chinese Patients With HBeAg+ve Chronic Hepatitis BChronic Hepatitis BNCT00857675GlaxoSmithKline480
已完成
2 期
Safety and Effectiveness of Giving Adefovir Dipivoxil Plus Abacavir Plus Efavirenz Plus Amprenavir to HIV-Infected Patients Who Have Failed to Respond to Previous Protease Inhibitor TreatmentHIV InfectionsNCT00002419Gilead Sciences25
已完成
1 期
A Study of Adefovir Dipivoxil in HIV-Infected Patients Who Have Not Been Treated With Anti-HIV DrugsHIV InfectionsNCT00002206Gilead Sciences45
已完成
3 期
Safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents With Chronic Hepatitis BChronic Hepatitis BNCT00095121Gilead Sciences173
已完成
4 期
Adefovir Dipivoxil For The Treatment Of Patients With Chronic Hepatitis B Related Advanced Fibrosis Or CirrhosisHepatitis B, ChronicFibrosisChronic Hepatitis BCirrhosisNCT00347009GlaxoSmithKline155